Page 25 - GTM-2-1

Global Translational Medicine Mineralocorticoid receptor in CMD

analysis. BMJ, 340: c1768. double-blind reminder study. Eur Heart J, 35: 2295–2302.
https://doi.org/10.1136/bmj.c1768 https://doi.org/10.1093/eurheartj/ehu164
141. Vukadinovic D, Lavall D, Vukadinovic AN, et al., 2017, 146. Filippatos G, Anker SD, Bohm M, et al., 2016, A randomized
True rate of mineralocorticoid receptor antagonists-related controlled study of finerenone vs. Eplerenone in patients
hyperkalemia in placebo-controlled trials: A meta-analysis. with worsening chronic heart failure and diabetes mellitus
Am Heart J, 188: 99–108. and/or chronic kidney disease. Eur Heart J, 37: 2105–2114.
https://doi.org/10.1016/j.ahj.2017.03.011 https://doi.org/10.1093/eurheartj/ehw132
142. Pitt B, Remme W, Zannad F, et al., 2003, Eplerenone, a 147. Bakris GL, Agarwal R, Anker SD, et al., 2020, Effect of
selective aldosterone blocker, in patients with left ventricular finerenone on chronic kidney disease outcomes in Type 2
dysfunction after myocardial infarction. N Engl J Med, diabetes. N Engl J Med, 383: 2219–2229.
348: 1309–1321.
https://doi.org/10.1056/NEJMoa2025845
https://doi.org/10.1056/nejmoa030207
148. Pitt B, Filippatos G, Agarwal R, et al., 2021, Cardiovascular
143. Zannad F, McMurray JJ, Krum H, et al., 2011, Eplerenone events with finerenone in kidney disease and Type 2
in patients with systolic heart failure and mild symptoms. diabetes. N Engl J Med, 385: 2252–2263.
N Engl J Med, 364: 11–21.
https://doi.org/10.1056/nejmoa2110956
https://doi.org/10.1056/NEJMoa1009492
149. Sueta D, Yamamoto E, Tsujita K, 2020, Mineralocorticoid
144. Adamopoulos C, Ahmed A, Fay R, et al., 2009, Timing of receptor blockers: Novel selective nonsteroidal
eplerenone initiation and outcomes in patients with heart mineralocorticoid receptor antagonists. Curr Hypertens
failure after acute myocardial infarction complicated by left Rep, 22: 21.
ventricular systolic dysfunction: Insights from the ephesus
trial. Eur J Heart Fail, 11: 1099–1105. https://doi.org/10.1007/s11906-020-1023-y
https://doi.org/10.1093/eurjhf/hfp136 150. Kintscher U, Bakris GL, Kolkhof P, 2022, Novel non-steroidal
mineralocorticoid receptor antagonists in cardiorenal
145. Montalescot G, Pitt B, Lopez de Sa E, et al., 2014, Early
eplerenone treatment in patients with acute ST-elevation disease. Br J Pharmacol, 179: 3220–3234.
myocardial infarction without heart failure: The randomized https://doi.org/10.1111/bph.15747

Volume 2 Issue 1 (2023) 19 https://doi.org/10.36922/gtm.v2i1.229